Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study. [electronic resource]
Producer: 20200616Description: 168-170 p. digitalISSN:- 1365-2141
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Cyclophosphamide -- therapeutic use
- Female
- Humans
- Interferon-alpha -- therapeutic use
- Lymphoma, Follicular -- drug therapy
- Male
- Middle Aged
- Prednisone -- therapeutic use
- Rituximab -- therapeutic use
- Treatment Outcome
- Vincristine -- therapeutic use
No physical items for this record
Publication Type: Letter; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.